Overview

Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis

Status:
Completed
Trial end date:
2013-09-01
Target enrollment:
Participant gender:
Summary
The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in patients with multiple sclerosis.
Phase:
Phase 2
Details
Lead Sponsor:
Avanir Pharmaceuticals
Treatments:
Dextromethorphan
Quinidine